Did you know?

Graphite Bio, Inc. 2.3700. +0.0200. +0.85%. In this article, we will take a look at the 12 gene editing stocks with the best long-term potential. To see more such companies, go directly to 5 Gene ...Editas Medicine Inc's trailing 12-month revenue is $24.6 million with a -792.7% profit margin. Year-over-year quarterly sales growth most recently was %.Sep 30, 2020 · Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ... The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 176.32% away from the 52-week low. What was the 52-week high for Editas Medicine ...Why Editas Medicine Stock Is Soaring Today. By Keith Speights – Sep 29, 2023 at 11:21AM Key Points. Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17.The latest price target for Editas Medicine ( NASDAQ: EDIT) was reported by Citigroup on Tuesday, October 24, 2023. The analyst firm set a price target for 11.00 …Editas Medicine stock has received a consensus rating of hold. The average rating score is and is based on 17 buy ratings, 21 hold ratings, and 7 sell ratings. What was the 52-week low for Editas ...That's why companies such as Editas Medicine ( EDIT 0.86%) and Intellia Therapeutics ( NTLA 2.54%) are down massively over the trailing 12-month period. However, Wall Street expects both to bounce ...The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the fourth quarter and full ...Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10 ...Editas Medicine's (NASDAQ: EDIT) lead candidate, EDIT-101, is a gene-editing therapy that targets a rare genetic disease called Leber congenital amaurosis 10, which leads to progressive blindness ...With shares down by 60% in the last three years, Editas Medicine (EDIT-0.75%) investors are experiencing a bumpy ride despite the company's impeccable gene-editing credentials. But for a biotech ...Like many other stocks, Editas Medicine was crushed over the last 18 months. Since the middle of 2021, EDIT plummeted from a high of about $72.50 to $8.43.Nov 24, 2023 · Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Editas Medicine (NASDAQ: EDIT), a genome-editing company, has seen a significant 20% surge in its stock, marking its largest increase over two years.This comes despite a 4.9% dip year-to-date and ...Editas (EDIT) delivered earnings and revenue surprises of 14.06% and 5.50%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Editas Medicine, Inc. and Azzur Cleanrooms on Demand, Azzur Group Company, Expand their Multi-Year Contract to Support Scaling of EDIT-301 Jul. 27: CI Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer Jul. 24Editas Medicine Inc (EDIT) advanced chart and technical analysis tool allows you to add studies and indicators such as Moving Averages (SMA and EMA), MACD, ...Editas Medicine works with two distinct CRISPR nucleases: Cas9 and Cas12a (also known as Cpf1). Both nucleases have distinct gene editing and targeting capabilities. Using these two nucleases, we can access a broad range of genetic mutations and develop targeted and durable gene edited medicines. We are researching and developing two types of ...Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 13.39% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.48. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.71. Year to date, Editas ...

At Editas Medicine, we are using this technology to develop transformative and durable medicines for people living with serious diseases. CRISPR (pronounced “crisper”) is an acronym for “Clustered, Regularly Interspaced, Short Palindromic Repeats,” and refers to a recently developed gene editing technology that can revise, remove, and ...Nov 3, 2023 · Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.81 per share a year ago. …

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Editas Medicine, Inc. (EDIT) Stock Price, Quote, News &a. Possible cause: Editas Medicine Inc (EDIT) advanced chart and technical analysis tool allo.